Download by
Scanning QR Code
No Stock Yet
Loading...
No Stock Yet
No Data
Largest borrow rate increases among liquid names
Latest data shows the largest indicative borrow rate increases among liquid option names include: (FRGE) 297.65% +18.05, Imperial Petroleum (IMPP) 95.00% +8.30, Novus Capital Corporation II (NRGV) 170
Why Orphan Drug Designation Offers Several Benefits
FinancialNewsMedia.com News Commentary PALM BEACH, Fla., May 18, 2022 /PRNewswire/ -- The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation. Here we discuss the FDA's Orphan Drug Designa
Analyst Ratings for CRISPR Therapeutics
Over the past 3 months, 11 analysts have published their opinion on CRISPR Therapeutics (NASDAQ:CRSP) stock. These analysts are typically employed by large Wall Street banks and tasked with understand
CRISPR Therapeutics hires Chief Medical Officer
Phuong Khanh Morrow has been appointed as Chief Medical Officer at biopharmaceutical company CRISPR Therapeutics (NASDAQ:CRSP).Morrow assumes the role on May 23, 2022 and will oversee the firm's globa
Crispr Therapeutics Is Maintained at Neutral by Citigroup
Crispr Therapeutics Is Maintained at Neutral by Citigroup
Crispr Therapeutics Price Target Cut to $53.00/Share From $64.00 by Citigroup
Crispr Therapeutics Price Target Cut to $53.00/Share From $64.00 by Citigroup
CRISPR Therapeutics analyst ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/17/2022 2.83% Citigroup $64 → $53 Maintains Neutral 05/13/2022 136.71% Needham $170 → $122 Maintains Bu
Citigroup Maintains Neutral on CRISPR Therapeutics, Lowers Price Target to $53
Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral and lowers the price target from $64 to $53.
CRISPR Therapeutics (CRSP) Stock: $53 Price Target From Citi
The shares of CRISPR Therapeutics (NASDAQ: CRSP) have received a $53 price target from Citi. These are the details. The shares of CRISPR Therapeutics (NASDAQ: CRSP) have received a $53 price target f
Citigroup Adjusts Price Target on CRISPR Therapeutics to $53 From $64, Maintains Neutral Rating
06:04 AM EDT, 05/17/2022 (MT Newswires) -- CRISPR Therapeutics AG (CRSP) has an average rating of outperform and price targets ranging from $52 to $220, according to analysts polled by Capital IQ. (MT